Pancreatic Enzymes (Pancrelipase) ： Bloating and Intestinal Gas

A エビデンス複数の大規模臨床試験が一貫して有意な効果を示しています。

Standard of care for exocrine pancreatic insufficiency. Pancreatic enzyme replacement therapy (25,000-40,000 lipase units/meal) normalizes fat absorption and helps resolve steatorrhea. FDA-approved medications (Creon, Zenpep).

𝕏 LinkedIn

<\/script>\n

`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dpancreatic\u002Denzymes\u0026condition\u003Dbloating\u002Dand\u002Dgas'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

結論

Key Study Findings

Randomized Controlled Trial 26 weeks Open-label

Assessing the impact of an intensive dietitian-led telehealth intervention focusing on nutritional adequacy, symptom control …

Dose: None vs: Usual nutrition care Outcome: Quality of life (EORTC-QLQ C30 summary score) 効果: None None

対象集団: Adults with pancreatic cancer (borderline/locally advanced/metastatic)

Case Reports n=1 Open-label

Case Report: A case of drug-induced pancreatitis caused by paroxetine with a literature review.

Dose: 20 mg once daily vs: None Outcome: Drug-induced pancreatitis 効果: None None

対象集団: 28-year-old woman with severe depression

Review

Rational Prescribing of Pancreatic Enzymes for Patients with Pancreatic Cancer.

Dose: Pancreatic enzyme replacement therapy (PERT) vs: None Outcome: EPI symptom management in pancreatic cancer 効果: None None

対象集団: Patients with pancreatic cancer and EPI

Case Reports

An Infected Intrahepatic Pancreatic Pseudocyst and Calcified Pancreas: A Rare Complication of Chronic Pancreatitis.

Dose: None vs: None Outcome: pain reduction 効果: None None

対象集団: None

Review

AGA Clinical Practice Update on the Epidemiology, Evaluation, and Management of Exocrine Pancreatic Insufficiency: Expert …

Dose: PERT (pancreatic enzyme replacement) vs: None Outcome: EPI diagnosis and treatment guidelines 効果: None None

対象集団: Patients with exocrine pancreatic insufficiency

Other n=35 26.0 weeks

Isolated Amylase Deficiency in Children and Its Clinical Implication.

Dose: None vs: None Outcome: Diarrhea outcomes 効果: None None

対象集団: children

Key Statistics

研究数

800

参加者数

↑

Positive

グレード

Referenced Papers

Assessing the impact of an intensive dietitian-led telehealth intervention focusing on nutritional adequacy, symptom control and optional supplemental jejunal feeding, … Other

Nutrition journal 2025

Case Report: A case of drug-induced pancreatitis caused by paroxetine with a literature review. Case Report

Frontiers in medicine 2025

Rational Prescribing of Pancreatic Enzymes for Patients with Pancreatic Cancer. Review

Pharmacy (Basel, Switzerland) 2024 2 件の引用

AGA Clinical Practice Update on the Epidemiology, Evaluation, and Management of Exocrine Pancreatic Insufficiency: Expert Review. Review

Gastroenterology 2023 87 件の引用

An Infected Intrahepatic Pancreatic Pseudocyst and Calcified Pancreas: A Rare Complication of Chronic Pancreatitis. Case Report

Cureus 2023 1 件の引用

Isolated Amylase Deficiency in Children and Its Clinical Implication. Other

Journal of pediatric … 2019 14 件の引用

Long alimentary limb duodenal switch (LADS): a short-term prospective randomized trial. RCT

Surgery for obesity … 2018 10 件の引用

Malnutrition in Pancreatic Ductal Adenocarcinoma (PDA): Dietary Pancreatic Enzymes Improve Short-Term Health but Stimulate Tumor Growth. Other

The American journal … 2018 9 件の引用

Diagnosis and management of pancreatic exocrine insufficiency. Other

The Medical journal … 2017 59 件の引用

Qualitative Assessment of the Symptoms and Impact of Pancreatic Exocrine Insufficiency (PEI) to Inform the Development of a Patient-Reported Outcome … Other

The patient 2017 55 件の引用

Systematic Review of Exocrine Pancreatic Insufficiency after Gastrectomy for Cancer. Systematic Review

Digestive surgery 2017 37 件の引用

A primer on exocrine pancreatic insufficiency, fat malabsorption, and fatty acid abnormalities. Review

The American journal … 2017 25 件の引用

[Small intestine bacterial overgrowth in patients with chronic pancreatitis]. Other

Revista medica de … 2008

Pancreatic supplements reduce symptomatic response of healthy subjects to a high fat meal. RCT

Digestive diseases and … 1999 40 件の引用

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

一般的な使用量

general:: 25,000-40,000 lipase units per meal
epiadults:: 25,000-50,000 lipase units with meals, 10,000-25,000 with snacks
epipediatric:: 500-2,500 lipase units/kg/meal (max 10,000 units/kg/day)

上限量： 10,000 lipase units/kg/day (higher doses associated with fibrosing colonopathy)

研究で検討された用量

用量	期間	効果	N
None	26 weeks	Mixed	--
20 mg once daily	--	Negative	1
Pancreatic enzyme replacement therapy (PERT)	--	Positive	--
None	--	Mixed	--
PERT (pancreatic enzyme replacement)	--	Positive	--
None	26.0 weeks	Mixed	35
16 g	8.7 weeks	Mixed	--
None	52.0 weeks	Mixed	20

推奨摂取タイミング： With meals and snacks; take half the dose at the beginning and half during the meal

Safety & Side Effects

報告されている副作用

⚠ Abdominal pain and cramping
⚠ Nausea
⚠ Fibrosing colonopathy at very high doses (rare; primarily in cystic fibrosis patients)
⚠ Hyperuricemia (high doses of protease can increase uric acid)

既知の相互作用

● Calcium carbonate and magnesium hydroxide antacids (may reduce enzyme activity)
● Acarbose and miglitol (pancreatic amylase may counteract alpha-glucosidase inhibitors)
● Iron supplements (protease may reduce iron absorption)
● Proton pump inhibitors (may improve enzyme efficacy by reducing acid denaturation)

耐容上限摂取量： 10,000 lipase units/kg/day (higher doses associated with fibrosing colonopathy)

サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。

Frequently Asked Questions

Does Pancreatic Enzymes (Pancrelipase) help with Bloating and Intestinal Gas?

Based on 12 studies with 800 participants, there is strong evidence from multiple clinical trials that Pancreatic Enzymes (Pancrelipase) may support Bloating and Intestinal Gas management. Our evidence grade is A (Strong Evidence).

How much Pancreatic Enzymes (Pancrelipase) should I take for Bloating and Intestinal Gas?

Studies have used various dosages. A commonly studied range is 25,000-40,000 lipase units per meal. Always consult your healthcare provider before starting any supplement regimen.

Are there side effects of Pancreatic Enzymes (Pancrelipase)?

Reported side effects may include Abdominal pain and cramping, Nausea, Fibrosing colonopathy at very high doses (rare; primarily in cystic fibrosis patients), Hyperuricemia (high doses of protease can increase uric acid). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.

How strong is the evidence for Pancreatic Enzymes (Pancrelipase) and Bloating and Intestinal Gas?

We rate the evidence as Grade A (Strong Evidence). This rating is based on 12 peer-reviewed studies with 800 total participants. The overall direction of effect is positive.

に関する他の成分： Bloating and Intestinal Gas

Ginger B Lactobacillus reuteri B Alpha-Galactosidase B Medium-Chain Triglycerides (MCT Oil) C

総合評価

Evidence Strength92%

High confidence

研究の内訳

RCT (2)Meta (0)Other (10)

代替成分との比較

この症状に対する他の成分との比較をご覧ください。

に関するすべての成分を見る： Bloating and Intestinal Gas

詳しく見る

References

[1] Emma McShane et al.. Nutr J. 2025. Assessing the impact of an intensive dietitian-led telehealth intervention focusing on nutritional adequacy, symptom control and optional supplemental jejunal feeding, … doi:10.1186/s12937-025-01113-9 PubMed
[2] Yangpeng Wu et al.. Front Med (Lausanne). 2025. Case Report: A case of drug-induced pancreatitis caused by paroxetine with a literature review. doi:10.3389/fmed.2025.1688065 PubMed
[3] Mary Acelle G Garcia et al.. Pharmacy (Basel). 2024. Rational Prescribing of Pancreatic Enzymes for Patients with Pancreatic Cancer. doi:10.3390/pharmacy12020047 PubMed
[4] David C Whitcomb et al.. Gastroenterology. 2023. AGA Clinical Practice Update on the Epidemiology, Evaluation, and Management of Exocrine Pancreatic Insufficiency: Expert Review. doi:10.1053/j.gastro.2023.07.007 PubMed
[5] Nabi Nadia et al.. Cureus. 2023. An Infected Intrahepatic Pancreatic Pseudocyst and Calcified Pancreas: A Rare Complication of Chronic Pancreatitis. doi:10.7759/cureus.35384 PubMed
[6] Puanani Hopson et al.. J Pediatr Gastroenterol Nutr. 2019. Isolated Amylase Deficiency in Children and Its Clinical Implication. doi:10.1097/MPG.0000000000002317 PubMed
[7] Anabelle Cloutier et al.. Surg Obes Relat Dis. 2018. Long alimentary limb duodenal switch (LADS): a short-term prospective randomized trial. doi:10.1016/j.soard.2017.08.028 PubMed
[8] Yalda Zolghadri et al.. Am J Pathol. 2018. Malnutrition in Pancreatic Ductal Adenocarcinoma (PDA): Dietary Pancreatic Enzymes Improve Short-Term Health but Stimulate Tumor Growth. doi:10.1016/j.ajpath.2017.11.014 PubMed
[9] Mehrdad Nikfarjam et al.. Med J Aust. 2017. Diagnosis and management of pancreatic exocrine insufficiency. doi:10.5694/mja16.00851 PubMed
[10] Colin D Johnson et al.. Patient. 2017. Qualitative Assessment of the Symptoms and Impact of Pancreatic Exocrine Insufficiency (PEI) to Inform the Development of a Patient-Reported Outcome … doi:10.1007/s40271-017-0233-0 PubMed
[11] Jennifer Straatman et al.. Dig Surg. 2017. Systematic Review of Exocrine Pancreatic Insufficiency after Gastrectomy for Cancer. doi:10.1159/000454958 PubMed
[12] Samer Alkaade et al.. Am J Manag Care. 2017. A primer on exocrine pancreatic insufficiency, fat malabsorption, and fatty acid abnormalities. PubMed
[13] Carla Mancilla A et al.. Rev Med Chil. 2008. [Small intestine bacterial overgrowth in patients with chronic pancreatitis]. PubMed
[14] F Suarez et al.. Dig Dis Sci. 1999. Pancreatic supplements reduce symptomatic response of healthy subjects to a high fat meal. doi:10.1023/a:1026675012864 PubMed

FDAに関する免責事項: これらの記述は米国食品医薬品局（FDA）による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。